Last updated: February 22, 2024
Sponsor: Ji Xing Pharmaceuticals Australia Pty Ltd
Overall Status: Active - Recruiting
Phase
1
Condition
Diabetes And Hypertension
Williams Syndrome
Vascular Diseases
Treatment
JX09
JX09 or placebo SAD
JX09 or placebo MAD
Clinical Study ID
NCT06183671
JX09002
Ages 18-55 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Male or female aged 18 to 55 years (inclusive)
- In good health as deemed by the Investigator through a medical evaluation, includingmedical history, physical examination, and laboratory tests
- Body mass index (BMI) between 18 and 32 kg/m2, with a minimum weight of 50 kg atScreening
Exclusion
Exclusion Criteria:
- Clinically significant oncologic, infectious, cardiovascular, pulmonary, hepatic,gastrointestinal, hematologic, metabolic, endocrine, neurologic, immunologic, renal,psychiatric, or other condition that in the opinion of the Investigator or MedicalMonitor would make is unsafe for the participant to join the study or fulfill itsrequirements.
- A clinical abnormality or abnormal laboratory parameter(s) in the opinion of theInvestigator or Medical Monitor is likely to introduce additional risk or will affectdata interpretation.
- Postural tachycardia or hypotension.
- Female of childbearing potential who is pregnant, lactating, or planning to becomepregnant.
Study Design
Total Participants: 92
Treatment Group(s): 3
Primary Treatment: JX09
Phase: 1
Study Start date:
January 18, 2024
Estimated Completion Date:
December 31, 2024
Connect with a study center
Nucleus Network Pty Ltd
Melbourne, 3004
AustraliaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.